Primary Site >> Colorectal Cancer
Gene >> TPI1
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. PMID: 15289858 |
Ref: Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. PMID: 15711180 |
Ref: Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. PMID: 17098463 |
Ref: Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. PMID: 20421638 Ref: Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics. PMID: 20682647 |
Ref: Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. PMID: 22977515 |
Ref: Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. PMID: 22735906 |
Ref: Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester. PMID: 25206290 Ref: Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. PMID: 25230742 |
Ref: Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. PMID: 25812794 Ref: Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA. PMID: 25901475 Ref: Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. PMID: 26163340 Ref: Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. PMID: 26557901 |
Ref: A novel antimetabolite: TAS-102 for metastatic colorectal cancer. PMID: 26677869 Ref: TAS-102 an Emerging Oral Fluoropyrimidine. PMID: 26722024 Ref: TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. PMID: 27126991 Ref: Review on TAS-102 development and its use for metastatic colorectal cancer. PMID: 27296058 |
Ref: Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells. PMID: 29119052 Ref: Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines. PMID: 29312810 |
Ref: Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer. PMID: 29491068 Ref: Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library. PMID: 29719626 Ref: Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. PMID: 29803544 Ref: Triose-phosphate isomerase is a novel target of miR-22 and miR-28, with implications in tumorigenesis. PMID: 29856481 Ref: Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. PMID: 30257515 |